Our History

Alison Pharmaceuticals prioritizes innovation in ophthalmic and injectable therapies. Committed to quality and accessibility, we redefine healthcare standards, delivering distinctive global value to patients and stakeholders.
2017

Foundation of Vision

The idea of establishing a Palestinian pharmaceutical company was born among a group of founders. This company was envisioned to develop and manufacture pharmaceutical items not previously produced in Palestine, contributing significantly to the local pharmaceutical industry.
2018

Strategic Investments and Company Formation

The idea was presented to a group of Palestinian investors, both from inside and outside Palestine, who were interested in developing the health sector and had relevant experience. This engagement led to an agreement on the objectives and plans for the project, culminating in the establishment of a limited liability company.
2019

Groundbreaking Developments

The engineering and technical designs for the project were approved. Construction and equipment operations commenced to establish two production lines: one for sterile eye drops and another for Small Volume Parenteral (SVP) glass ampoules, along with a research and development laboratory.
2021

Market Entry

The company obtained final licenses from the Palestinian Ministry of Health and launched its first product, Alifresh, in the local market in March.
2022

Expansion of Production Capabilities

The company’s Board of Directors decided to add a third production line for Large Volume Parenteral (LVP) solutions, marking the first production line of its kind in Palestine and the surrounding countries.
2023

Going Global

The company began exporting some of its products to foreign markets
2024

Growth and Sales

Sales of LVP products commenced.